Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03350815 · ClinicalTrials.gov registry record · Phase 4

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

A Phase 4 study of Ankylosing Spondylitis, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
322
Enrollment target
20
Study locations

NCT03350815 is a Phase 4 study of Ankylosing Spondylitis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 322 participants, below the 38,176-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03350815, a Phase 4 study of Ankylosing Spondylitis, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
322 participants
Enrollment target
20
Study locations

Study Summary

This was a study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

Conditions Studied

Ankylosing Spondylitis

Interventions

  • DRUG 150 mg open-label secukinumab
  • DRUG 150 mg double-blinded secukinumab
  • DRUG 300 mg double-blinded secukinumab

Study Locations (20)

Florida

  • Novartis Investigative Site - Aventura
  • Novartis Investigative Site - Boca Raton
  • Novartis Investigative Site - Brandon
  • Novartis Investigative Site - DeLand
  • Novartis Investigative Site - Gainesville
  • Novartis Investigative Site - Orlando
  • Novartis Investigative Site - Plantation
  • Novartis Investigative Site - St. Petersburg
  • Novartis Investigative Site - Tamarac
  • Novartis Investigative Site - Tampa
  • Novartis Investigative Site - Zephyrhills

California

  • Novartis Investigative Site - Fullerton
  • Novartis Investigative Site - Loma Linda
  • Novartis Investigative Site - Palm Desert
  • Novartis Investigative Site - Tustin
  • Novartis Investigative Site - Upland

Illinois

  • Novartis Investigative Site - Springfield
  • Novartis Investigative Site - Vernon Hills

Arkansas

  • Novartis Investigative Site - Jonesboro

Georgia

  • Novartis Investigative Site - Duluth

Trial Details

FieldValue
Enrollment Target 322 participants
Start Date 2018-03-13
Est. Completion 2021-05-29
Phase Phase 4

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03350815

The ClinicalTrials.gov registry entry for NCT03350815 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38,176-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (99% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ankylosing Spondylitis appearing as the primary indexed condition, and to 3 interventions - of which 150 mg open-label secukinumab is the first listed.

NCT03350815 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT03350815 about?

NCT03350815 is a clinical study titled "Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis". This was a study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

What is the current status of trial NCT03350815?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 322 participants. The study started on 2018-03-13. Estimated completion is 2021-05-29.

What conditions does trial NCT03350815 study?

This clinical trial studies the following conditions: Ankylosing Spondylitis.

What interventions are being tested in trial NCT03350815?

The interventions under investigation include: 150 mg open-label secukinumab (DRUG), 150 mg double-blinded secukinumab (DRUG), 300 mg double-blinded secukinumab (DRUG).

Who is sponsoring clinical trial NCT03350815?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03350815 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ankylosing Spondylitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ankylosing Spondylitis

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.